57 related articles for article (PubMed ID: 22015771)
1. Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders.
Bochtler T; Kirsch M; Maier B; Bachmann J; Klingmüller U; Anderhub S; Ho AD; Krämer A
Leukemia; 2012 Apr; 26(4):728-35. PubMed ID: 22015771
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative disorders: the centrosome connection.
Delaval B; Lelièvre H; Birnbaum D
Leukemia; 2005 Oct; 19(10):1739-44. PubMed ID: 16107884
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome.
Delaval B; Létard S; Lelièvre H; Chevrier V; Daviet L; Dubreuil P; Birnbaum D
Cancer Res; 2005 Aug; 65(16):7231-40. PubMed ID: 16103074
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase fusion genes in chronic myeloproliferative diseases.
Cross NC; Reiter A
Leukemia; 2002 Jul; 16(7):1207-12. PubMed ID: 12094244
[TBL] [Abstract][Full Text] [Related]
5. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
6. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cgamma at the centrosome.
Lelièvre H; Chevrier V; Tassin AM; Birnbaum D
Mol Cancer; 2008 Apr; 7():30. PubMed ID: 18412956
[TBL] [Abstract][Full Text] [Related]
8. Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.
Lee JY; Hong WJ; Majeti R; Stearns T
PLoS One; 2014; 9(3):e92641. PubMed ID: 24658090
[TBL] [Abstract][Full Text] [Related]
9. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
10. The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation.
Pecquet C; Nyga R; Penard-Lacronique V; Smithgall TE; Murakami H; Régnier A; Lassoued K; Gouilleux F
Oncogene; 2007 Mar; 26(11):1577-85. PubMed ID: 16953222
[TBL] [Abstract][Full Text] [Related]
11. Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase.
Kouhara H; Kurebayashi S; Hashimoto K; Kasayama S; Koga M; Kishimoto T; Sato B
Oncogene; 1995 Jun; 10(12):2315-22. PubMed ID: 7784079
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone.
Yamauchi T; Ueki K; Tobe K; Tamemoto H; Sekine N; Wada M; Honjo M; Takahashi M; Takahashi T; Hirai H; Tushima T; Akanuma Y; Fujita T; Komuro I; Yazaki Y; Kadowaki T
Nature; 1997 Nov; 390(6655):91-6. PubMed ID: 9363897
[TBL] [Abstract][Full Text] [Related]
14. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.
Lonardo F; Di Marco E; King CR; Pierce JH; Segatto O; Aaronson SA; Di Fiore PP
New Biol; 1990 Nov; 2(11):992-1003. PubMed ID: 1983208
[TBL] [Abstract][Full Text] [Related]
15. Transformation of Ba/F3 cells and Rat-1 cells by ETV6/ARG.
Iijima Y; Okuda K; Tojo A; Tri NK; Setoyama M; Sakaki Y; Asano S; Tokunaga K; Kruh GD; Sato Y
Oncogene; 2002 Jun; 21(28):4374-83. PubMed ID: 12080468
[TBL] [Abstract][Full Text] [Related]
16. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
17. v-fps causes transformation by inducing tyrosine phosphorylation and activation of the PDGFbeta receptor.
Anderson DH; Ismail PM
Oncogene; 1998 May; 16(18):2321-31. PubMed ID: 9620549
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
19. TTK kinase is essential for the centrosomal localization of TACC2.
Dou Z; Ding X; Zereshki A; Zhang Y; Zhang J; Wang F; Sun J; Huang H; Yao X
FEBS Lett; 2004 Aug; 572(1-3):51-6. PubMed ID: 15304323
[TBL] [Abstract][Full Text] [Related]
20. Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update.
Anastasiadou E; Schwaller J
Curr Opin Hematol; 2003 Jan; 10(1):40-8. PubMed ID: 12483110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
